RaySense:

Continuous, objective UV and light exposure data for clinical trials

A medical-grade wearable that captures UVB, UVA, RGB and infrared light across 13 individually calibrated optical channels. RaySense delivers precise, real-time dosimetry for clinical trials where UV exposure is a primary endpoint or confounding variable.

Ennova Health 2023 Winner of IoT Category in e-Health, Wearables and Robotics

Quantifying Real-World UV Exposure to Improve Clinical Trial Quality

RaySense provides sponsors with continuous measurement of real-world light exposure in clinical trials, delivering fidelity that has not previously been possible. UV exposure is the most impactful environmental factor in photosensitive disease research, yet it remains the most poorly measured confounding variable in clinical trials. A small, discreet design combined with flexible wearing options ensures correct anatomical positioning without participant burden.

Isolate drug efficacy from environmental noise

Objectively quantifies real-world UV exposure, a critical variable impacting outcomes in photosensitive diseases such as Lupus and Psoriasis, and safety trials involving TNF-alpha inhibitors. Where UV is unmeasured, it becomes an uncontrolled confounder that undermines efficacy endpoints.

Versatile and comfortable

Scratching is more complex than a binary yes/no. ScratchSense captures seven dimensions of each scratch event, including intensity (Hz), force (N), amplitude (cm), duration, and whether nails were used, giving you endpoints that reflect the full clinical picture.

Accurate, multi-spectrum data

Measures UVB (erythemal weighted, 280-400 nm) and UVA alongside RGB and infrared light across 12 channels, plus flicker and artificial light detection. 13 optical channels in total, each individually calibrated.

Tailored spectrum response

Using atmospheric models and 13 individually measured optical channels, RaySense can provide modelled spectrum response curves tailored to mimic those of specific dermatoses. Dose thresholds and participant notifications are configurable per protocol.

Real-time dose monitoring

Configurable dose thresholds trigger participant notifications when UV limits are approached. Daily and weekly dose graphs are available in the app. Optional real-time UV Index display keeps participants informed throughout the study.

Increase Patient Compliance and Engagement

Enable High-Quality Data Capture

A small and discreet sensor design, combined with flexible wearing options, ensures correct anatomical positioning without burdening participants. Integrated compliance sensors verify that data is valid throughout the study period.

Flexible wearing options

Available as a finger ring (16 sizes), wristband, clip with rubberised grip, or pendant necklace. Flexible wearing positions ensure the sensor is correctly placed for the indication under study.

Real-time data sync

Sensor data is sent to the participant's smartphone via Bluetooth Low Energy and processed through Stingray Observatory for secure, audit-ready logging.

Compliance verification

A proximity sensor and skin temperature sensor detect whether the optical sensors are covered and whether sampling is valid. The 6-axis accelerometer monitors wearing behaviour and flags invalid readings automatically.

Personalised push notifications

Alerts participants as they approach protocol-defined UV dose thresholds. Configurable per study. Daily and weekly dose graphs provide a visual record of cumulative exposure.

quotes
We selected the Replior solution because integrating the UV sensor with the study ePRO app simplified access and supported participant retention and engagement, while streamlining UV exposure monitoring for our study team.

Diego Herrera Egea

Director of Clinical Data & Digital Innovation Almirall

Sun exposure: the confounding variable rarely measured

UV exposure modulates disease severity across a wide range of conditions. Without objective measurement, it remains an uncontrolled variable that undermines efficacy endpoints, complicates safety monitoring, and weakens statistical power.

Dermatological Research

Atopic Dermatitis, Psoriasis, Eczema, Rosacea, PLE, Solar Urticaria. UV directly modulates disease severity, confounding efficacy endpoints for topical and systemic therapies. Seasonal variation adds uncontrolled noise.

Phototherapy Trials

Vitiligo, Atopic Dermatitis, Psoriasis, PLE, Mastocytosis. The efficacy of phototherapy depends on precise UV dosing. Uncontrolled ambient UV exposure between clinic sessions directly impacts outcomes and makes it difficult to assess the true dose-response relationship.

Melanoma and Skin Cancer Trials

UV is the primary environmental risk factor for skin cancer. Unmeasured exposure complicates safety monitoring and confounds the analysis of tumour recurrence across treatment arms.

Autoimmune Photosensitivity

Lupus, Sjogren's syndrome. Photosensitivity prevalence is as high as 83% in Lupus patients. UV exposure can trigger both cutaneous lesions and systemic flares, representing a direct threat to trial validity.

Erythropoietic Protoporphyria (EPP)

Monitor light sensitivity to measure treatment response and verify that patients remain within safe exposure limits throughout the study period.

Xeroderma Pigmentosum (XP)

Collect objective exposure data while verifying that participants remain within protocol-defined UV limits throughout the study.

Immunosuppressant Therapy

Beyond increasing long-term cancer risk, immunosuppressants can act as photosensitising agents. Skin cancer risk can be up to 65 times higher in immunosuppressed patients. In Australia, up to 70% of fair-skinned transplant recipients develop skin cancer within 20 years.

Photosensitising Medications

Certain antibiotics, NSAIDs, and diuretics can induce photosensitivity, leading to unexpected adverse events that mimic side effects of the investigational product and confound safety data. Objective UV measurement separates drug effect from light-induced effect.

Designed for Comfort and Durability

RaySense is compact (26 x 20 x 8 mm) and built for extended wear. The anodised 6061 aluminium casing is rated IP68 waterproof. It is available in four wearing configurations and connects via Bluetooth Low Energy.

Extended battery life

Operates for approximately two months per charge (configuration dependent), covering most study periods without interruption. Charges via USB-C.

13-channel optical sensor

13 individually calibrated optical channels covering UVB (280-400 nm, erythemal weighted), UVA, RGB and infrared (400-1050 nm, 12 channels), plus flicker and artificial light detection. Spectrum response curves can be tailored to specific dermatoses.

Real-time, accurate data

Dynamic sampling with averaged or spot UVI, RGB and infrared logging. Optional real-time UV Index display in the app. Daily and weekly dose graphs configurable per study.

Durable and user-friendly design

Constructed with anodised 6061 aluminium housing, IP68 rated, and easy to clean.

Bluetooth connectivity

Bluetooth Low Energy with a range of approximately 5 m. Data syncs automatically to the native Android and iOS app. Optional wired data download available via the charger.

Compliance verification

A proximity sensor and skin temperature sensor detect whether optical sensors are covered and whether sampling is valid. The 6-axis accelerometer monitors wearing behaviour and flags invalid data automatically.

Advancing Clinical Research with a Unified Sensor Portfolio

RaySense is part of Replior’s clinical sensor platform. Alongside RaySense, ScratchSense captures scratching behaviour and sleep quality in pruritus trials. Together they give clinical teams objective, device-reported endpoints to complement patient-reported outcomes.

Related Products

Smart phone showing Trial Online ePRO app, with the home page open

Replior eCOA/ePRO

Integrate sensor data with patient feedback

ScratchSense

Nocturnal scratch and sleep tracking for pruritus trials

FAQ

RaySense continuously measures UVB, UVA, RGB and infrared light across 13 individually calibrated optical channels. Data is processed through Stingray Observatory, Replior’s sensor backend, which logs every receipt and processing step for a complete, audit-ready record.
RaySense is suited to any trial where UV or light exposure is a confounding variable or primary endpoint. This includes dermatology (Atopic Dermatitis, Psoriasis, Rosacea, PLE), melanoma and skin cancer, autoimmune photosensitivity (Lupus, Sjogren’s), phototherapy trials, immunosuppressant therapy, and photoaging research.
RaySense transmits data via Bluetooth Low Energy to the participant’s smartphone. Data is then processed through Stingray Observatory, Replior’s sensor backend, which applies versioned algorithms and maintains a compliance-grade audit trail. Optional wired download is available via the charger.
RaySense is compact (26 x 20 x 8 mm) and available in four wearing configurations: finger ring (16 sizes), wristband, clip with rubberised grip, or pendant necklace. Proximity and skin temperature sensors verify that the device is worn correctly throughout the study.
Proximity and skin temperature sensors verify correct wearing throughout the study. Configurable dose thresholds alert participants when UV limits are approached. The compact, discreet form factor and four wearing options minimise the likelihood of participants removing the device.

Ready to add objective UV data to your trial?

Ready to add objective UV data to your trial?